Peptide-targeted sites in vivo include three different types: firstly, tumor-targeted peptides (various tumor cell surface receptor targeting), secondly, TME-targeted peptides (including tumor vascular system targets, tumor extracellular matrix (ECM) targets, and tumor-associated cell targets), and thirdly, subcellular organelle-targeted peptides (plasma membrane, nucleus, mitochondria, etc.)[70]. The gene discussed is CD177; the disease is neoplasm.